Pfizer Reaches Pricing Agreement With Trump Administration

Pfizer Inc. said it has reached a pricing agreement with the Trump Administration aimed at reducing prescription drug costs for U.S. patients while bolstering domestic pharmaceutical investment. 

Under the voluntary deal, Pfizer will align prices of newly launched medicines with those in other developed countries and offer significant discounts—averaging 50% and up to 85%—on a broad range of primary care and select specialty treatments through a new direct purchasing platform, TrumpRx.gov. Specific financial terms were not disclosed. 

“We are proud to join President Trump at the White House to celebrate this landmark agreement that is a win for American patients, a win for American leadership, and a win for Pfizer,” said Albert Bourla, Pfizer’s Chairman and CEO. 

The agreement also includes a three-year tariff exemption for Pfizer products under Section 232 investigation, contingent on increased U.S. manufacturing investment. Pfizer said it will commit an additional $70 billion to U.S. research, development, and capital projects over the coming years, building on $83 billion invested from 2018 to 2024. 

“This agreement allows us to invest even more boldly in the United States – fueling growth, creating jobs, and returning manufacturing home,” Bourla said. 

Pfizer said the deal provides pricing and trade stability, enabling it to focus on advancing treatments in oncology, obesity, vaccines, and immunology.